• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT A receptor.配体门控离子通道调控的新机制;5-氯吲哚对5-羟色胺A受体的作用。
Br J Pharmacol. 2016 Dec;173(24):3467-3479. doi: 10.1111/bph.13638. Epub 2016 Nov 1.
2
5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.5-氯吲哚:一种强效的5-羟色胺3型受体变构调节剂。
Br J Pharmacol. 2013 Jul;169(6):1228-38. doi: 10.1111/bph.12213.
3
Auto-inhibition at a ligand-gated ion channel: a cross-talk between orthosteric and allosteric sites.配体门控离子通道的自抑制:正构位点与别构位点之间的相互作用。
Br J Pharmacol. 2015 Jan;172(1):93-105. doi: 10.1111/bph.12896. Epub 2014 Nov 24.
4
Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.5-羟色胺3型受体的变构激动剂和正变构调节剂TMPPAA的功能特性及作用机制的描述
Biochem Pharmacol. 2016 Jun 15;110-111:92-108. doi: 10.1016/j.bcp.2016.04.004. Epub 2016 Apr 13.
5
Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site.发现 5-HT3 受体的新型变构调节剂:通过保守的跨膜亚基间位点抑制和增强 Cys 环受体信号传导。
J Biol Chem. 2012 Jul 20;287(30):25241-54. doi: 10.1074/jbc.M112.360370. Epub 2012 May 15.
6
Conformational Changes in the 5-HT Receptor Extracellular Domain Measured by Voltage-Clamp Fluorometry.电压钳荧光法测量 5-HT 受体细胞外结构域构象变化。
Mol Pharmacol. 2019 Dec;96(6):720-734. doi: 10.1124/mol.119.116657. Epub 2019 Oct 3.
7
Orthosteric and Allosteric Activation of Human 5-HTA Receptors.人 5-HT1A 受体的变构激活和正构激活。
Biophys J. 2020 Oct 20;119(8):1670-1682. doi: 10.1016/j.bpj.2020.08.029. Epub 2020 Sep 2.
8
Activation of human 5-hydroxytryptamine type 3 receptors via an allosteric transmembrane site.通过变构跨膜位点激活人 5-羟色胺 3 型受体。
Mol Pharmacol. 2015 Jan;87(1):87-95. doi: 10.1124/mol.114.094540. Epub 2014 Oct 22.
9
The L293 residue in transmembrane domain 2 of the 5-HT3A receptor is a molecular determinant of allosteric modulation by 5-hydroxyindole.5-羟色胺3A受体跨膜结构域2中的L293残基是5-羟吲哚变构调节的分子决定因素。
Neuropharmacology. 2008 Jun;54(8):1153-65. doi: 10.1016/j.neuropharm.2008.03.009. Epub 2008 Mar 27.
10
Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.人类5-HT3A受体天然存在的Pro391Arg变体的药理学和电生理特性。
Pharmacogenetics. 2004 Mar;14(3):165-72. doi: 10.1097/00008571-200403000-00004.

引用本文的文献

1
Eggs Sialoglycoprotein Prevent Estrogen Deficiency-Induced High Bone Turnover by Controlling OPG/RANKL/TRAF6 Pathway and Serum Metabolism.卵唾液酸糖蛋白通过调控骨保护素/核因子κB受体活化因子配体/肿瘤坏死因子受体相关因子6信号通路及血清代谢来预防雌激素缺乏诱导的高骨转换。
Front Nutr. 2022 Apr 12;9:871521. doi: 10.3389/fnut.2022.871521. eCollection 2022.
2
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.国际基础和临床药理学联合会。CX. 5-羟色胺受体分类:药理学与功能。
Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552.

本文引用的文献

1
The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels.《2015/16 药理学简明指南:配体门控离子通道》
Br J Pharmacol. 2015 Dec;172(24):5870-903. doi: 10.1111/bph.13350.
2
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.《2016年IUPHAR/BPS药理学指南:迈向1300个蛋白质靶点与6000种配体之间的精准定量相互作用》
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.
3
Activation and modulation of recombinantly expressed serotonin receptor type 3A by terpenes and pungent substances.萜类化合物和辛辣物质对重组表达的5-羟色胺3A受体的激活与调节作用
Biochem Biophys Res Commun. 2015 Nov 27;467(4):1090-6. doi: 10.1016/j.bbrc.2015.09.074. Epub 2015 Oct 9.
4
Experimental design and analysis and their reporting: new guidance for publication in BJP.实验设计与分析及其报告:发表于《英国药理学杂志》的新指南
Br J Pharmacol. 2015 Jul;172(14):3461-71. doi: 10.1111/bph.12856.
5
An Accessory Agonist Binding Site Promotes Activation of α4β2* Nicotinic Acetylcholine Receptors.一个辅助激动剂结合位点促进α4β2*烟碱型乙酰胆碱受体的激活。
J Biol Chem. 2015 May 29;290(22):13907-18. doi: 10.1074/jbc.M115.646786. Epub 2015 Apr 13.
6
Allosteric activation of the 5-HT3AB receptor by mCPBG.mCPBG对5-HT3AB受体的变构激活作用。
Neuropharmacology. 2015 Apr;91:103-8. doi: 10.1016/j.neuropharm.2014.12.018. Epub 2014 Dec 23.
7
Subunit interfaces contribute differently to activation and allosteric modulation of neuronal nicotinic acetylcholine receptors.亚基界面在神经元烟碱型乙酰胆碱受体的激活和变构调节中发挥不同作用。
Neuropharmacology. 2015 Apr;91:157-68. doi: 10.1016/j.neuropharm.2014.11.027. Epub 2014 Dec 5.
8
Activation of human 5-hydroxytryptamine type 3 receptors via an allosteric transmembrane site.通过变构跨膜位点激活人 5-羟色胺 3 型受体。
Mol Pharmacol. 2015 Jan;87(1):87-95. doi: 10.1124/mol.114.094540. Epub 2014 Oct 22.
9
Block of GABA(A) receptor ion channel by penicillin: electrophysiological and modeling insights toward the mechanism.青霉素对GABA(A)受体离子通道的阻断:关于其机制的电生理及模型研究见解
Mol Cell Neurosci. 2014 Nov;63:72-82. doi: 10.1016/j.mcn.2014.10.001. Epub 2014 Oct 8.
10
Auto-inhibition at a ligand-gated ion channel: a cross-talk between orthosteric and allosteric sites.配体门控离子通道的自抑制:正构位点与别构位点之间的相互作用。
Br J Pharmacol. 2015 Jan;172(1):93-105. doi: 10.1111/bph.12896. Epub 2014 Nov 24.

配体门控离子通道调控的新机制;5-氯吲哚对5-羟色胺A受体的作用。

Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT A receptor.

作者信息

Powell Andrew D, Grafton Gillian, Roberts Alexander, Larkin Shannon, O'Neill Nathanael, Palandri Josephine, Otvos Reka, Cooper Alison J, Ulens Chris, Barnes Nicholas M

机构信息

Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

School of Nursing Midwifery and Social Work, Birmingham City University, Edgbaston, UK.

出版信息

Br J Pharmacol. 2016 Dec;173(24):3467-3479. doi: 10.1111/bph.13638. Epub 2016 Nov 1.

DOI:10.1111/bph.13638
PMID:27677804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5120152/
Abstract

BACKGROUND AND PURPOSE

The 5-HT receptor is a prototypical member of the Cys-loop ligand-gated ion channel (LGIC) superfamily and an established therapeutic target. In addition to activation via the orthosteric site, receptor function can be modulated by allosteric ligands. We have investigated the pharmacological action of Cl-indole upon the 5-HT A receptor and identified that this positive allosteric modulator possesses a novel mechanism of action for LGICs.

EXPERIMENTAL APPROACH

The impact of Cl-indole upon the 5-HT receptor was assessed using single cell electrophysiological recordings and [ H]-granisetron binding in HEK293 cells stably expressing the 5-HT receptor.

KEY RESULTS

Cl-indole failed to evoke 5-HT A receptor-mediated responses (up to 30 μM) or display affinity for the [ H]-granisetron binding site. However, in the presence of Cl-indole, termination of 5-HT application revealed tail currents mediated via the 5-HT A receptor that were independent of the preceding 5-HT concentration but were antagonized by the 5-HT receptor antagonist, ondansetron. These tail currents were absent in the 5-HT AB receptor. Furthermore, the presence of 5-HT revealed a concentration-dependent increase in the affinity of Cl-indole for the orthosteric binding site of the human 5-HT A receptor.

CONCLUSIONS AND IMPLICATIONS

Cl-indole acts as both an orthosteric agonist and an allosteric modulator, but the presence of an orthosteric agonist (e.g. 5-HT) is a prerequisite to reveal both actions. Precedent for ago-allosteric action is available, yet the essential additional presence of an orthosteric agonist is now reported for the first time. This widening of the pharmacological mechanisms to modulate LGICs may offer further therapeutic opportunities.

摘要

背景与目的

5-羟色胺受体是半胱氨酸环配体门控离子通道(LGIC)超家族的典型成员,也是一个既定的治疗靶点。除了通过正构位点激活外,受体功能还可由变构配体调节。我们研究了氯吲哚对5-羟色胺A受体的药理作用,并确定这种正变构调节剂具有一种LGICs的新作用机制。

实验方法

使用单细胞电生理记录和[H] - 格拉司琼结合实验,在稳定表达5-羟色胺受体的HEK293细胞中评估氯吲哚对5-羟色胺受体的影响。

关键结果

氯吲哚未能引发5-羟色胺A受体介导的反应(高达30μM),也未显示对[H] - 格拉司琼结合位点的亲和力。然而,在存在氯吲哚的情况下,5-羟色胺应用的终止显示通过5-羟色胺A受体介导的尾电流,这些尾电流与先前的5-羟色胺浓度无关,但被5-羟色胺受体拮抗剂昂丹司琼拮抗。这些尾电流在5-羟色胺AB受体中不存在。此外,5-羟色胺的存在显示氯吲哚对人5-羟色胺A受体正构结合位点的亲和力呈浓度依赖性增加。

结论与启示

氯吲哚既作为正构激动剂又作为变构调节剂起作用,但正构激动剂(如5-羟色胺)的存在是揭示这两种作用的先决条件。变构激动作用的先例是存在的,但正构激动剂的必要额外存在现在首次被报道。这种调节LGICs的药理机制的拓宽可能提供更多的治疗机会。